CDH17 and thyroid cancer: Once the effectiveness of these cadherin RGD-specific monoclonal antibodies in cancer models overexpressing CDH17 and VE-cadherin has been demonstrated, the next step should be to investigate the efficacy of these antibodies in other cancers positive for high CDH6 expression, such as ovarian, renal or thyroid cancers.